S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:ARDS

Aridis Pharmaceuticals (ARDS) Stock Forecast, Price & News

$0.29
+0.01 (+3.57%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.24
$0.30
50-Day Range
$0.16
$0.40
52-Week Range
$0.15
$2.77
Volume
2.74 million shs
Average Volume
2.90 million shs
Market Capitalization
$10.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Aridis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,970.4% Upside
$6.00 Price Target
Short Interest
Healthy
2.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.97mentions of Aridis Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars


ARDS stock logo

About Aridis Pharmaceuticals (NASDAQ:ARDS) Stock

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA.

Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARDS Stock News Headlines

Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Aridis Provides Corporate Update
Why Aridis Pharmaceuticals Shares Are Soaring Today
See More Headlines

ARDS Price History

ARDS Company Calendar

Last Earnings
11/10/2021
Today
6/02/2023
Next Earnings (Estimated)
6/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDS
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,982.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-30,370,000.00
Net Margins
-982.56%
Pretax Margin
-982.56%

Debt

Sales & Book Value

Annual Sales
$3.09 million
Book Value
($1.16) per share

Miscellaneous

Free Float
31,424,000
Market Cap
$10.39 million
Optionable
Not Optionable
Beta
0.93

Key Executives

  • Vu L. TruongVu L. Truong
    Director, Chief Executive & Scientific Officer
  • Fred Kurland
    Chief Financial & Accounting Officer
  • Hasan Jafri
    Chief Medical Officer
  • Steven M. Chamow
    Vice President-Research & Development
  • Lisa Sher
    Head-Investor & Public Relations













ARDS Stock - Frequently Asked Questions

Should I buy or sell Aridis Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDS shares.
View ARDS analyst ratings
or view top-rated stocks.

What is Aridis Pharmaceuticals' stock price forecast for 2023?

2 analysts have issued 1 year price objectives for Aridis Pharmaceuticals' stock. Their ARDS share price forecasts range from $2.00 to $10.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 1,982.6% from the stock's current price.
View analysts price targets for ARDS
or view top-rated stocks among Wall Street analysts.

How have ARDS shares performed in 2023?

Aridis Pharmaceuticals' stock was trading at $1.18 at the start of the year. Since then, ARDS stock has decreased by 75.6% and is now trading at $0.2881.
View the best growth stocks for 2023 here
.

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 756,200 shares, an increase of 87.0% from the April 30th total of 404,400 shares. Based on an average trading volume of 881,700 shares, the short-interest ratio is presently 0.9 days.
View Aridis Pharmaceuticals' Short Interest
.

When is Aridis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 5th 2023.
View our ARDS earnings forecast
.

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) issued its earnings results on Wednesday, November, 10th. The company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $1.43. The firm earned $0.52 million during the quarter.

What other stocks do shareholders of Aridis Pharmaceuticals own?
When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Who are Aridis Pharmaceuticals' major shareholders?

Aridis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Sabby Management LLC (7.12%), Commonwealth Equity Services LLC (2.15%) and Simplex Trading LLC (0.00%). Insiders that own company stock include John F Hamilton and Vu Truong.
View institutional ownership trends
.

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $0.29.

How much money does Aridis Pharmaceuticals make?

Aridis Pharmaceuticals (NASDAQ:ARDS) has a market capitalization of $10.39 million and generates $3.09 million in revenue each year. The company earns $-30,370,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The official website for the company is www.aridispharma.com. The company can be reached via phone at (408) 385-1742, via email at jwong@bplifescience.com, or via fax at 408-960-3822.

This page (NASDAQ:ARDS) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -